SuperworthStryker EPS SYK
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- $9.65
- Latest quarter, Q2 FY26
- $3.30
- +44% on a year earlier
- Fiscal year 2025
- $8.40
- +8% on the year before
Stryker's earnings per share was $9.65 over the twelve months to Jun 30, 2026, up 28% on a year earlier.
In its latest quarter, Q2 FY26, it was $3.30, up 44% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 15% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $8.40 | +8% |
| FY2024 | $7.76 | −6% |
| FY2023 | $8.25 | +34% |
| FY2022 | $6.17 | +18% |
| FY2021 | $5.21 | +24% |
| FY2020 | $4.20 | −23% |
| FY2019 | $5.48 | −41% |
| FY2018 | $9.34 | +249% |
| FY2017 | $2.68 | −38% |
| FY2016 | $4.35 | +15% |
| FY2015 | $3.78 | +182% |
| FY2014 | $1.34 | −49% |
| FY2013 | $2.63 | −22% |
| FY2012 | $3.39 | −2% |
| FY2011 | $3.46 | +8% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $3.30 | +44% | $9.65 | |
| Q1 FY26 | $1.93 | +14% | $8.64 | |
| Q4 FY25 | $2.20 | +56% | $8.40 | |
| Q3 FY25 | $2.22 | +3% | $7.61 | |
| Q2 FY25 | $2.29 | +7% | $7.55 | |
| Q1 FY25 | $1.69 | −18% | $7.40 | |
| Q4 FY24 | $1.41 | −53% | $7.76 | |
| Q3 FY24 | $2.16 | +20% | $9.33 | |
| Q2 FY24 | $2.14 | +11% | $8.97 | |
| Q1 FY24 | $2.05 | +33% | $8.76 | |
| Q4 FY23 | $2.98 | +103% | $8.25 | |
| Q3 FY23 | $1.80 | −16% | $6.74 |
Against its peers
Companies in Medical - Devices nearest Stryker's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SYKStryker | $9.65 | +28% a year |
| MDTMedtronic | $4.07 | +12% a year |
| ABTAbbott Laboratories | $2.68 | −66% a year |
| BSXBoston Scientific | $2.47 | +47% a year |
| EWEdwards Lifesciences | $1.74 | −75% a year |
| GEHCGE HealthCare Technologies | $4.36 | −11% a year |
| DXCMDexCom | $2.52 | +76% a year |
| ZBHZimmer Biomet | $4.11 | +0% a year |
| Peer median | $2.68 |
Where Stryker ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Stryker
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.